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Background: Glucose variability could be an independent risk factor for diabetes complications in addition to
average glucose. The deficiency in islet β cell secretion and insulin sensitivity, the two important pathophysiological
mechanisms of diabetes, are responsible for glycemic disorders. The oral disposition index evaluated by product of
insulin secretion and sensitivity is a useful marker of islet β cell function. The aim of the study is to investigate
glycemic variability in relation to oral disposition index in the subjects across a range of glucose tolerance from the
normal to overt type 2 diabetes.
Methods: 75-g oral glucose tolerance test (OGTT) was performed in total 220 subjects: 47 with normal glucose
regulation (NGR), 52 with impaired glucose metabolism (IGM, 8 with isolated impaired fasting glucose [IFG], 18 with
isolated impaired glucose tolerance [IGT] and 26 with combined IFG and IGT), 61 screen-diagnosed diabetes by
isolated 2-h glucose (DM2h) and 60 newly diagnosed diabetes by both fasting and 2-h glucose (DM). Insulin
sensitivity index (Matsuda index, ISI), insulin secretion index (ΔI30/ΔG30), and integrated β cell function measured
by the oral disposition index (ΔI30/ΔG30 multiplied by the ISI) were derived from OGTT. All subjects were
monitored using the continuous glucose monitoring system for consecutive 72 hours. The multiple parameters of
glycemic variability included the standard deviation of blood glucose (SD), mean of blood glucose (MBG), high
blood glucose index (HBGI), continuous overlapping net glycemic action calculated every 1 h (CONGA1), mean of
daily differences (MODD) and mean amplitude of glycemic excursions (MAGE).
Results: From the NGR to IGM to DM2h to DM group, the respective values of SD (mean ± SD) (0.9 ± 0.3, 1.5 ± 0.5,
1.9 ± 0.6 and 2.2 ± 0.6 mmol/), MBG (5.9 ± 0.5, 6.7 ± 0.7, 7.7 ± 1.0 and 8.7 ± 1.5 mmol/L), HGBI [median(Q1–Q3)][0.8
(0.2–1.2), 2.0(1.2–3.7), 3.8(2.4–5.6) and 6.4(3.2–9.5)], CONGA1 (1.0 ± 0.2, 1.3 ± 0.2, 1.5 ± 0.3 and 1.8 ± 0.4 mmol/L),
MODD (0.9 ± 0.3, 1.4 ± 0.4, 1.8 ± 0.7 and 2.1 ± 0.7 mmol/L) and MAGE (2.1 ± 0.6, 3.3 ± 1.0, 4.3 ± 1.4 and 4.8 ±
1.6 mmol/L) were all increased progressively (all p < 0.05), while their oral disposition indices [745(546–947), 362
(271–475), 203(134–274) and 91(70–139)] were decreased progressively (p < 0.05). In addition, SD, MBG, HGBI,
CONGA1, MODD and MAGE were all negatively associated with the oral disposition index in each group (all
p < 0.05) and in the entire data set (r = −0.66, –0.66, –0.72, –0.59, –0.61 and −0.65, respectively, p < 0.05).
Conclusions: Increased glycemic variability parameters are consistently associated with decreased oral disposition
index in subjects across the range of glucose tolerance from the NGR to IGM to DM2h to DM group.
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The deficiency in islet β cell secretion and insulin sensi-
tivity, the two important pathophysiological mechanisms
of diabetes, are responsible for disorders of glycemic me-
tabolism [1-3]. Both β cell secretion dysfunction and in-
sulin resistance can be demonstrated long before overt
diabetes and may differ in the different stages of glucose
tolerance from the normal glucose regulation (NGR) via
impaired glucose metabolism (IGM) to early screen-
diagnosed diabetes by 2-h glucose (DM2h) to overt dia-
betes by fasting and 2-h glucose (DM).
Insulin secretion and insulin resistance can be quanti-
fied with the hyperglycemic and euglycemic insulin
clamp techniques, respectively [4]. However, these tech-
niques are labor intensive and are difficult to apply in
clinical practices or in large epidemiological studies.
Surrogate measures of insulin secretion and insulin sen-
sitivity have been developed from oral glucose tolerance
test (OGTT) [5]. The product of insulin secretion and
sensitivity derived from OGTT (ΔI30/ΔG30 × ISI), also
termed oral disposition index, is a useful marker of inte-
grated islet β cell function [6]. The oral disposition index
as a composite measure may be a better index than
either ΔI30/ΔG30 or ISI alone to reflect the notion of
declining β cell function and account for glycemic dete-
riorations from the normal to overt diabetes.
Glucose variability could be an independent risk factor
for diabetes complications in addition to average glucose
[7-9]. The continuous glucose monitoring (CGM) sys-
tem can detect glycemic variability in more details than
the conventional self-monitoring methods of blood glu-
cose [10,11]. Glycemic variability parameters, which
could be calculated from CGM data [12], may differ in
the progression from the normal to overt diabetes.
In this study, we investigated the multiple glycemic
variability parameters in relation to oral disposition
index in the subjects across a range of glucose tolerance
from the NGR to IGM to DM2h to overt DM group.
Methods
Study subjects
Total 220 subjects were recruited in this study from
January 2012 to January 2013: 47 with normal glucose
regulation (NGR), 52 with impaired glucose metabolism
(IGM, 8 with isolated impaired fasting glucose [IFG], 18
with isolated impaired glucose tolerance [IGT] and 26
with combined IFG and IGT), 61 screen-diagnosed dia-
betes by isolated 2-h glucose (DM2h) and 60 newly diag-
nosed diabetes by both fasting and 2-h glucose (DM).
The diagnosis of IFG, IGT and type 2 diabetes were
based on the ADA diagnostic criteria 2011 [13]. The oral
glucose tolerance test (OGTT) screen program was
mainly performed in subjects with diabetes risk factors,
such as first-degree relative with diabetes, body massindex > 24 kg/m2, dyslipidemia, hypertension, et al. Pa-
tients with IGM or DM2h were screened and diagnosed
by twice 75-g OGTT. Patients with symptomic hypergly-
cemia and overt diabetes were diagnosed by once 75-g
OGTT. Patients have no acute complications, such as
diabetic ketoacidosis, or other disorders affecting glucose
metabolism, and did not received anti-diabetic drug
treatment. The study was approved by the institutional
review board of the Second Affiliated Hospital of
Nantong University, with written informed consent be-
ing obtained from all participants.
Baseline measurements
Baseline measurements, including height, weight, and
blood pressure, were obtained from all subjects in light
clothing and without shoes. Body mass index (BMI) was
calculated by dividing weight (kg) by height squared
(m2). Systolic blood pressure (SBP) and diastolic blood
pressure (DBP) were taken three times using a sphygmo-
manometer and then averaged for further analysis.
β cell function determination
All subjects were examined by the 75-g oral glucose test.
Blood samples were taken at 0, 30, 60, 90, and 120 min
for the measurement of plasma glucose and insulin con-
centrations (glucose unit: mmol/L, insulin unit: miu/L).
Insulin sensitivity was estimated using the insulin sensi-
tivity index (ISI) of Matsuda and DeFronzo: ISI = 10,000/
square root of (Ins0 × Glu0) × (mean glucose × mean in-
sulin during OGTT) [14]. Insulin secretion was estimated
by the insulinogenic index calculated from the ratio of in-
crements of serum insulin to glucose measured at 30 min
by the follows: ΔI30/ΔG30 = (Ins30-Ins0)/(Glu30-Glu0)
[15]. Integrated β cell function was measured by the oral
disposition index as the product of Insulin secretion and
insulin sensitivity ((ΔI30/ΔG30) × ISI) [6].
Continuous glucose monitoring (CGM) in subjects
All subjects were monitored by CGM system (Medtronic
MiniMed, Northridge, CA 91325, USA) for 72 hours
after OGTT. The CGM system sensor was inserted in all
patients on day 0 and removed on day 3. Data were
downloaded and glucose profiles were evaluated based
on the data collected on day 1 and 2. The patients were
instructed to input at least four calibration readings per
day and the times of key events. During the study, all
subjects had standard meals provided by dietary division.
The total calorie intake was 30 kcal/kg per day, with
50% carbohydrates, 15% proteins, and 35% fats. The cal-
orie distribution between breakfast, lunch, and dinner
was 20%, 40%, and 40%, respectively. Three daily meals
were required to consume at time of 6:30 to 7:30, 11:30
to 12:30, and 18:00 to 19:00, respectively.
Table 1 Clinical characteristics in subjects with different stages of glucose tolerance
NGR IGM DM2h DM P
N 47 52 61 60 –
Age(year) 45 ± 10 46 ± 13 48 ± 13 44 ± 12 0.093
Female(%) 22(46.8) 21(40.4) 26(51.0) 28(46.7) 0.886
BMI(kg/m2) 24.8 ± 3.4 25.2 ± 2.8 24.7 ± 2.5 25.0 ± 4.4 0.182
SBP(mmHg) 119 ± 12 126 ± 13* 125 ± 15* 132 ± 18* 0.001
DBP(mmHg) 75 ± 10 77 ± 9 79 ± 10* 80 ± 8* 0.015
TG(mmol/L) 1.4(0.8–2.2) 1.5(0.9–2.5) 1.9(1.1–3.3)*‡ 1.8(1.4–4.0)*‡ 0.002
TC(mmol/L) 4.5 ± 1.2 4.7 ± 1.0 5.1 ± 1.3* 5.3 ± 2.0*‡ 0.022
HDL-C(mmol/L) 1.4 ± 0.4 1.2 ± 0.3* 1.1 ± 0.3* 1.1 ± 0.3* 0.013
LDL-C(mmol/L) 2.3 ± 0.8 2.5 ± 0.8 2.8 ± 1.0*‡ 2.6 ± 0.7* 0.020
HbA1c(%) 5.3 ± 0.5 6.3 ± 1.1* 7.6 ± 1.6*‡ 8.9 ± 1.8*‡§ 0.000
ISI 168(122–222) 131(97–203)* 108(74–162)*‡ 92(67–142)*‡ 0.002
ΔI30/ΔG30 4.5(3.7–5.8) 2.6(1.4–4.4)* 1.6(1.1–3.1)*‡ 1.0(0.5–1.9)*‡§ 0.000
oral disposition index 745(546–947) 362(271–475)* 203(134–274)*‡ 91(70–139)*‡§ 0.000
SD(mmol/L) 0.9 ± 0.3 1.5 ± 0.5* 1.9 ± 0.6*‡ 2.2 ± 0.6*‡§ 0.000
MBG(mmol/L) 5.9 ± 0.5 6.7 ± 0.7* 7.7 ± 1.0*‡ 8.7 ± 1.5*‡§ 0.000
HBGI 0.8(0.2–1.2) 2.0(1.2–3.7)* 3.8(2.4–5.6)*‡ 6.4(3.2–9.5)*‡§ 0.000
CONGA1(mmol/L) 1.0 ± 0.2 1.3 ± 0.2* 1.5 ± 0.3*‡ 1.8 ± 0.4*‡§ 0.000
MODD(mmol/L) 0.9 ± 0.3 1.4 ± 0.4* 1.8 ± 0.7*‡ 2.1 ± 0.7*‡§ 0.000
MAGE(mmol/L) 2.1 ± 0.6 3.3 ± 1.0* 4.3 ± 1.4*‡ 4.8 ± 1.6*‡§ 0.000
Normally distributed values in the table are given as the mean ± SD, and the non-normally distributed values are given as the median (25% and
75% interquartiles).
NGR normal glucose regulation, IGM impaired glucose metabolism, DM2h screen-diagnosed diabetes by isolated 2-h glucose, DM newly diagnosed diabetes by
both fasting and 2-h glucose.
BMI body mass index, SBP/DBP systolic/diastolic blood pressure, TC total cholesterol, TG triglyceride, HDL-C high density lipoprotein cholesterol, LDL-C low density
lipoprotein cholesterol, HbA1c glycosylated hemoglobin A1c, ISI insulin sensitivity index, ΔI30/ΔG30 serum insulin to glucose measured at 30 min, SD standard
deviation of blood glucose, MBG mean of blood glucose, HBGI high blood glucose index, CONGA1 continuous overlapping net glycemic action calculated every
1 h, MODD mean of daily differences, MAGE mean amplitude of glycemic excursions.
Sex distribution was compared by Chi-squared test; comparison to NGR: *p < 0.05; comparison to IGM: ‡p < 0.05; comparison to DM2h: §p < 0.05.
Figure 1 Hyperbolic relationship between insulin secretion
index(ΔI30/ΔG30) and insulin sensitivity index(ISI) in subjects
with different stages of glucose tolerance. NGR: normal glucose
regulation; IGM: impaired glucose metabolism; DM2h: screen-diag
nosed diabetes by isolated 2-h glucose; DM: newly diagnosed
diabetes by both fasting and 2-h glucose.
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standard deviation of blood glucose (SD), mean of daily
continuous 24 hours blood glucose (MBG), high blood
glucose index (HBGI), continuous overlapping net gly-
cemic action calculated every 1 h (CONGA1), mean of
daily differences (MODD) and mean amplitude of gly-
cemic excursions (MAGE) [12]. Continuous overlapping
net glycemic action (CONGA) was calculated by deter-
mining the difference between values at different set in-
tervals [16], and CONGA1 was calculated every 1 h
during the monitoring period. High blood glucose index
(HBGI) was used to assess the hyperglycemic risk [17].
The mean of daily differences (MODD) was calculated
from the absolute difference between paired continuous
glucose monitoring values during two successive 24 hour
periods and was used to assess inter-day glycemic vari-
ability [18]. The mean amplitude of glycemic excur-
sions (MAGE), which was designed to quantify major
swings of glycemia and to exclude minor ones, was
used for assessing intra-day glycemic variability in
this study [19,20]. It should be noted that MBG is a
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ically variability.
Laboratory examination
Capillary glucose concentrations were measured with
Lifescan Surestep blood glucose meter. Glycosylated
hemoglobin A1c (HbA1c) was measured by the high
performance liquid chromatography (HPLC) with D-10
hemoglobin Testing Program (Bio-Rad). Serum glucose
concentrations were measured by the glucose oxidase
method. Serum insulin concentrations were measured
by magnetic beads-based enzymatic spectrofluorometric
immunoassay with automatic enzyme immunoassay
apparatus (AIA360, TOSOH). Total cholesterol (TC),
triglyceride (TG), high density lipoprotein cholesterol
(HDL-C), and low density lipoprotein cholesterol (LDL-
C) were measured with Hitachi Model 7600 Series Auto-
matic Analyzer.Table 2 Correlation coefficients among the glycemic variabili
MBG CONGA1
r p r p

























NGR normal glucose regulation, IGM impaired glucose metabolism, DM2h screen-di
both fasting and 2-h glucose, SD standard deviation of blood glucose, MBG mean o
overlapping net glycemic action calculated every 1 h, MODD mean of daily differenStatistical analyses
Data analyses were performed using the SPSS16.0 statis-
tical software (SPSS Inc., USA). Continuous variables
were expressed as means ± standard deviation (SD) or
median (interquartile range) in the case of skewed distri-
butions, and sex ratio were expressed as n (%). Natural
logarithmic transformations were applied for all non-
normally distributed variables.
The validity of the oral disposition index was assessed
by demonstrating whether a hyperbolic relationship
existed between OGTT-based measures of insulin secre-
tion and insulin sensitivity. Regression analysis was applied
to combinations of insulin secretion and insulin sensitivity
to determine the regression coefficient β for the following
model: ln(insulin secretion) = constant + β × ln(insulin sen-
sitivity). The hyperbolic relationship can be established if
estimated β is approximately equal to −1and with 95%
confidence interval (CI) excluding 0 [21,22].ty in subjects with different stages of glucose tolerance
HBGI MODD MAGE
r p r p r p
0.71 <0.001 0.76 <0.001 0.83 <0.001
0.70 <0.001 0.29 0.048 0.64 <0.001
0.69 <0.001 0.56 <0.001 0.37 0.011
0.40 0.005 0.64 <0.001
0.57 <0.001
0.95 <0.001 0.87 <0.001 0.85 <0.001
0.76 <0.001 0.68 <0.001 0.52 <0.001
0.71 <0.001 0.74 <0.001 0.56 <0.001
0.84 <0.001 0.68 <0.001
0.52 <0.001
0.82 <0.001 0.84 <0.001 0.78 <0.001
0.76 <0.001 0.58 <0.001 0.48 <0.001
0.77 <0.001 0.37 0.003 0.55 <0.001
0.70 <0.001 0.55 <0.001
0.59 <0.001
0.83 <0.001 0.78 <0.001 0.84 <0.001
0.89 <0.001 0.60 <0.001 0.40 <0.001
0.85 <0.001 0.57 <0.001 0.44 <0.001
0.66 <0.001 0.66 <0.001
0.57 <0.001
0.84 <0.001 0.84 <0.001 0.86 <0.001
0.80 <0.001 0.75 <0.001 0.68 <0.001
0.73 <0.001 0.67 <0.001 0.58 <0.001
0.74 <0.001 0.75 <0.001
0.74 <0.001
agnosed diabetes by isolated 2-h glucose, DM newly diagnosed diabetes by
f blood glucose, HBGI high blood glucose index, CONGA1 continuous
ces, MAGE mean amplitude of glycemic excursions.
Table 3 The ratios of MAGE, MODD and CONGA1 to SD in subjects with different stages of glucose tolerance
NGR IGM DM2h DM P Total
MAGE/SD 2.26 ± 0.060 2.23 ± 0.060 2.23 ± 0.064 2.25 ± 0.060 0.988 2.24 ± 0.031
MODD/SD 0.99 ± 0.030 0.93 ± 0.026 0.92 ± 0.030 0.92 ± 0.026 0.320 0.94 ± 0.014
CONGA1/SD 0.93 ± 0.02 0.88 ± 0.02 0.89 ± 0.02 0.87 ± 0.03 0.350 0.89 ± 0.01
The ratios in the table are given as the mean ± SEM.
NGR normal glucose regulation, IGM impaired glucose metabolism, DM2h screen-diagnosed diabetes by isolated 2-h glucose, DM newly diagnosed diabetes by
both fasting and 2-h glucose, SD standard deviation of blood glucose, MBG mean of blood glucose, HBGI high blood glucose index, CONGA1 continuous
overlapping net glycemic action calculated every 1 h, MODD mean of daily differences, MAGE mean amplitude of glycemic excursions.
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applied to compare differences of continuous variables
among groups, and the least significant difference (LSD)
test for multiple comparisons was further performed.
Chi-squared test was applied to compare sex distribution
among groups. Relationships between glycemic variabil-
ity and oral disposition index were assessed using the
Pearson’s correlation test. p < 0.05 was considered to be
statistically significant.Results
Baseline characteristics of the subjects
As shown in Table 1, age, sex distribution and BMI were
comparable among the four groups. The blood pressure
(SBP and DBP) in the IGM, DM2h and DM groups were
generally higher than those in the NGR group. The lipid
metabolic disorders were also observed in the IGM,
DM2h and DM groups. The glycosylated hemoglobin
A1c (HbA1c) was increased progressively from the NGR
to IGM to DM2h to DM group (Table 1).β cell function index derived from OGTT in the subjects
Insulin secretion index (ΔI30/ΔG30) was decreased
progressively from the NGR to IGM to DM2h to DM
group (p < 0.05). Matsuda index (ISI) in the NGR and
IGM groups were higher than in DM2h and DM
groups (p < 0.05), and the DM2h and DM groups had
no differences in ISI (p > 0.05) (Table 1).Table 4 Relationships between glycemic variability and oral d
glucose tolerance
NGR IGM
r p r p r
SD −0.29 0.048 −0.38 0.006 −0.
MBG −0.56 <0.001 −0.35 0.012 −0.
HBGI −0.30 0.043 −0.32 0.023 −0.
CONGA1 −0.47 0.001 −0.34 0.015 −0.
MODD −0.33 0.022 −0.48 <0.001 −0.
MAGE −0.55 <0.001 −0.41 0.003 −0.
HBGI and oral disposition index were ln-transformed.
NGR normal glucose regulation, IGM impaired glucose metabolism, DM2h, screen-di
both fasting and 2-h glucose, SD standard deviation of blood glucose, MBG mean o
overlapping net glycemic action calculated every 1 h, MODD mean of daily differenThe oral disposition index was decreased progressively
from the NGR to IGM to DM2h to DM group (p < 0.01)
(Table 1). Figure 1 displays the hyperbolic relationship
between insulin secretion and insulin sensitivity for each
glucose tolerance group using the product of the ΔI30/
ΔG30 and ISI. The hyperbolic curves demonstrated a
shift to the left and downward from the NGR to IGM to
DM2h to DM. The corrected slopes included −1 for the
relationship between ln(ΔI30/ΔG30) and ln(ISI) in the
NGR (−1.15 [95% CI −1.39 to −0.91]), IGM (−1.23
[−1.44, –1.03]), DM2h (−0.99 [−1.19, –0.80]) and DM
(−1.10 [−1.31, –0.90]). So the validity of the oral dispos-
ition index was documented.
Glycemic variability in the subjects
The multiple glycemic variability parameters from CGM
data were shown in Table 1. After comparison within
the four groups, SD, MBG, HGBI, CONGA1, MODD
and MAGE were all increased progressively from the
NGR to IGM to DM2h to DM group (p < 0.05).
Inter-relationships among glycemic variability in the
subjects
The Spearman’s correlation coefficients among the pa-
rameters of glycemic variability were analyzed to meas-
ure whether they have agreements in characterizing
glycemic variability (Table 2). There are high degrees of
agreement among SD, MBG, HGBI, CONGA1, MODD
and MAGE, with almost correlations being significant atisposition index in subjects with different stages of
DM2h DM Total
p r p r p
36 0.005 −0.45 <0.001 −0.66 <0.001
42 0.001 −0.40 0.001 −0.66 <0.001
47 <0.001 −0.47 <0.001 −0.72 <0.001
43 0.001 −0.32 0.014 −0.59 <0.001
30 0.018 −0.41 0.001 −0.61 <0.001
34 0.007 −0.40 0.002 −0.65 <0.001
agnosed diabetes by isolated 2-h glucose, DM newly diagnosed diabetes by
f blood glucose, HBGI high blood glucose index, CONGA1 continuous
ces, MAGE mean amplitude of glycemic excursions.
Figure 2 (See legend on next page.)
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Figure 2 The overall best-fit lines obtained by nonlinear regression analysis between glycemic variability parameters (a: SD, b: MBG,
c: HGBI, d: CONGA1, e: MODD and f: MAGE) and oral disposition index. NGR: normal glucose regulation; IGM: impaired glucose metabolism;
DM2h: screen-diagnosed diabetes by isolated 2-h glucose; DM: newly diagnosed diabetes by both fasting and 2-h glucose. SD: standard deviation
of blood glucose; MBG: mean of blood glucose; HBGI: high blood glucose index; CONGA1: continuous overlapping net glycemic action calculated
every 1 h; MODD: mean of daily differences; MAGE: mean amplitude of glycemic excursions.
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the entire data set.
In the majority of published studies, the standard devi-
ation (SD) around the mean glucose value was consid-
ered as a classical and well-validated index to assess the
glycemic variability. The ratios of MAGE, MODD and
CONGA1 to SD were also analyzed in the study sub-
jects. There were direct linear proportionalities between
MAGE, MODD, CONGA1 and SD for the each glucose
tolerance group or the entire data set. The ratios of
MAGE, MODD and CONGA1 to SD were 2.24 ± 0.031
(SEM), 0.94 ± 0.014 and 0.89 ± 0.01, respectively, in the
entire data set. And the ratios of MAGE/SD, MODD/SD
and CONGA1/SD were comparable in the NGR, IGM,
DM2h and DM groups (ANOVA p = 0.988, p = 0.320
and 0.350, respectively) (Table 3).Relationships between glycemic variability and oral
disposition index
When the relationships between glycemic variability pa-
rameters and oral disposition index were analyzed by
Pearson’s correlation test, SD, MBG, HGBI, CONGA1,
MODD and MAGE were all negatively associated with
oral disposition index in each group (p < 0.05) and in the
entire data set (p < 0.05) (Table 4). These relationships
remained significant after adjusting for age, sex, BMI,
SBP, DBP, TG, TC, HDLC, LDLC and HbA1c.
The overall best-fit lines obtained by nonlinear re-
gression analysis (logarithmic regression) between
glycemic variability parameters and oral disposition
index are presented in the Figure 2a–f. The overall
regression line between SD and oral disposition index
was y = −0.57ln(x) + 4.83(r = −0.66, p < 0.001), overall
regression line between MBG and oral disposition
index was y = −1.26ln(x) + 14.42 (r = −0.66, p < 0.001),
overall regression line between HBGI and oral dis-
position index was ln(y) = −0.99ln(x) + 6.31 (r = −0.72,
p < 0.001), overall regression line between CONGA1
and oral disposition index was y = −0.26ln(x) + 2.77
(r = −0.59, p < 0.001), overall regression line between
MODD and oral disposition index was y = −0.52ln(x) +
4.40 (r = −0.61, p < 0.001), overall regression line
between MAGE and oral disposition index was
y = −1.31ln(x) + 10.81(r = −0.65, p < 0.001). The cor-
relation coefficients were almost in agreements
(Figure 2a–f ).Discussion
The glycemic disorders in diabetes are not solely limited
to fasting and postprandial hyperglycemia, but can be
extended to the glycemic variability that includes both
upward (postprandial glucose increments) and down-
ward (interprandial glucose decrements) changes [23].
Glucose variability could be an independent risk factor
for diabetes complications in addition to average glucose
[7-9]. Glucose fluctuations are presented not only in dia-
betes patients but also in normoglycemic and prediabe-
tes subjects [24], and the characteristics of glucose
metabolic disorders may differ in the progression from
normal to overt diabetes. Our study recruited the sub-
jects across a range of glucose tolerance from the NGR
to IGM to DM2h to overt DM group. The results of our
study showed glycemic variability parameters, including
SD, MBG, HGBI, CONGA1, MODD and MAGE, in-
creased progressively from the NGR to IGM to DM2h
to DM group. The results of our study are consistent
with those of Wang et al. [25]. Wang et al. showed the
diabetes patients had increased postprandial glucose ex-
cursion, higher glucose levels overnight and greater
inter-day fluctuations compared with the normoglycemic
and impaired glucose regulation individuals. Our find-
ings could have a major impact on our understanding of
the overall glycemic variability changes from the NGR to
IGM to DM2h to overt DM group and how this could
influence different complication consequences.
In addition to metabolic differences, other factors such
as meals consumed and drug treatment may be partly
responsible for the glycemic variability [26]. We em-
ployed a fixed meal regimen in the study and recruited
diabetes patients (DM2h and DM groups) who had not
received anti-diabetic drug treatment thereby controlling
for the dietary and drug effect on glycemic variability.
Thus, changes of glycemic variability due to metabolic
differences from the normal to overt diabetes were well
demonstrated in our study.
The inter-relationships among measures of variability
were further assessed to weigh whether they have agree-
ment in characterizing glycemic variability. The results
documented that the agreements among the measures
were at high degree in each glucose tolerance group and
in the entire data set. The results were consistent with
those from Hill et al. [11] and Kohnert et al. [27]. In the
majority of published studies, the SD around the mean
glucose value was considered as a classical and well-
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The ratios of MAGE, MODD and CONGA1 to SD were
2.24 ± 0.031 (SEM), 0.94 ± 0.014 and 0.89 ± 0.01, respect-
ively, in the entire data set. The ratios that we have iden-
tified fit well with previously reported values of Rodbard
et al. [28-30], Fritzsche et al. [31] and Kohnert et al.
[27]. The ratio of MAGE/SD was also comparable in
NGR, IGM, DM2h and DM groups. And the ratios of
MODD/SD and CONGA1/SD were also similar in the
four groups. Thus, our findings imply that SD,
CONGA1, MODD and MAGE could be used as vali-
dated indices to assess the glycemic variability in sub-
jects with different stages of glucose tolerance.
The progression from the NGR via IGM to DM2h to
overt diabetes was considered due to the deterioration of
insulin secretion and increasing of insulin insensitivity.
Insulin secretion index (ΔI30/ΔG30), a surrogate marker
of early insulin response, has been validated against
gold-standard measures of insulin secretion obtained
from intravenous glucose tolerance testing [32]. The de-
creased insulin secretion capacity plays a definite role in
the development of type 2 diabetes [33,34]. Matsuda
index, a marker of whole-body insulin sensitivity, is
highly correlated with the rate of whole-body glucose
disposal during the euglycemic insulin clamp [14]. Kim
et al. [6] found that increased risk for type 2 diabetes
was evidenced by a lower oral disposition index (ΔI30/
ΔG30 × ISI). Our study demonstrated that the oral dis-
position index declined progressively from the NGR to
IGM (IFG/IGT) to early screen-diagnosed diabetes by
isolated 2-h post-challenge glucose to overt diabetes by
fasting and 2-h glucose. The hyperbolic curves
representing the oral disposition index are shifted to the
left and downward from the NGR to IGM to DM2h to
DM (Figure 1). This shift is also a hallmark of type 2 dia-
betes pathophysiology and is considered one of the earli-
est indicators of β-cell dysfunction [35].
After correlation analysis, SD, MBG, HGBI, CONGA
1, MODD and MAGE were all negatively associated with
the oral disposition index in the separate group (NGR,
IGM, DM2h or DM) and in the entire data set. These
findings imply that diabetic treatment aims to improve β
cell function may flat glycemic variability.
It should be pointed out that our study has some limi-
tations. The IGM group should be theoretically divided
into subgroups with isolated IFG or IGT, but the small
sample size of subgroups might make some differences
insignificant. We put them into one study group consid-
ering that IFG and IGT are intermediate states that exist
between normal glucose tolerance and overt diabetes.
Another limitation related to oral disposition index is
that circulating insulin levels during the OGTT may be
affected by other factors apart from β cell function, such
as incretin hormones and hepatic extraction. The twofactors may limit the degree to which insulin levels dur-
ing the OGTT can reflect β cell function. But the validity
of the oral disposition index had been assessed by dem-
onstrating that the hyperbolic relationship existed be-
tween OGTT-based measures of insulin secretion and
insulin sensitivity (Figure 1).
Conclusion
In summary, our study has demonstrated that increased
glycemic variability parameters are consistently associated
with decreased oral disposition index in the subjects
across the range of glucose tolerance from the NGR to
IGM to DM2h to DM group, which not only provides im-
portant clues for clinics but also forms a strong basis for
further investigations of glycemic disorders.
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